Current approaches for new TB drugs

dc.contributor.author	Pandey, Shilpika
dc.contributor.author	Soni, Isha
dc.contributor.author	Topno, Neha
dc.contributor.author	Dasgupta, Arunava
dc.contributor.author	Chopra, Sidharth
dc.date.accessioned	2015-05-11T07:40:01Z
dc.date.available	2015-05-11T07:40:01Z
dc.date.issued	2014
dc.identifier.citation	Current Respiratory Medicine Reviews, 2014, 10(2), 88-96	en
dc.identifier.uri	http://hdl.handle.net/123456789/1448
dc.description.abstract	Tuberculosis is essentially a curable disease but inspite of a WHO approved DOTS therapy, it still continues to ravage mankind. This situation is exacerbated by long course of chemotherapy, increasing drug resistance and co-emergence with HIV. The TB drug pipeline remained stagnant for a long time with no new drug approved till FDA approval for Bedaquiline. This situation has now improved with a number of agents in pre-clinical and clinical development against M. tuberculosis. In this review, we are focusing on some of the newer drugs in discovery and preclinical development against M. tuberculosis.	en
dc.format.extent	353668 bytes
dc.format.mimetype	application/pdf
dc.language.iso	en	en
dc.relation.ispartofseries	CSIR-CDRI Communication No. 8803	en
dc.subject	Clinical Strains	en
dc.subject	MIC	en
dc.subject	Mycobacterium	en
dc.subject	Drugs	en
dc.subject	Pre-Clinical Development	en
dc.subject	Tuberculosis	en
dc.title	Current approaches for new TB drugs	en
dc.type	Article	en